Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial

Tashkin, D.P.; Kanner, Richard E.; Bailey, William C.; Buist, Sonia; Anderson, Paula; Nides, Mitchell; Gonzales, David; Dozier, G; Patel, MK; Jamerson, Brenda D.

doi:10.1016/s0140-6736(00)04724-3

Cited by 374 publications

(248 citation statements)

References 16 publications

Supporting

Mentioning

211

Contrasting

Unclassified

Order By: Relevance

“…However, smoking cessation is far from easy and smoking cessation programmes generally have poor success rates [9][10][11]. Evidence also suggests that chronic inflammation persists after smoking has stopped [12], which will continue to contribute to lung function decline.…”

Section: Introductionmentioning

confidence: 99%

Tiotropium improves FEV1 in patients with COPD irrespective of smoking status

Moita¹,

Bárbara²,

Cardoso³

et al. 2008

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

This study evaluated whether the effect of tiotropium on the change in trough forced expiratory volume in 1 s (FEV 1 ), vs. placebo, is affected by smoking status. In a 3-month, double-blind study in 31 centres in Portugal, 311 (289 completed) patients were randomised to tiotropium 18 mg once daily or placebo. Baseline mean (standard deviation (SD)) FEV 1 was 1.11 (0.39) l in the tiotropium group and 1.13 (0.39) l in the placebo group. Patients had an average smoking history of 55 (25.7) pack-years; 80 (26%) were smokers and 224 (74%) were ex-smokers. The primary end-point was change in morning pre-dose (i.e. trough) FEV 1 after 12 weeks. Trough FEV 1 at 12 weeks was significantly improved with tiotropium vs. placebo: the difference in means was 102 ml, P ¼ 0.0011, 95% confidence interval (CI) (41, 164). The difference in means in smokers was 138 ml, P ¼ 0.0105, CI (32, 244); in ex-smokers it was 66 ml, P ¼ 0.0375, CI (3, 129). The difference between smokers and ex-smokers was not statistically significant (P ¼ 0.6982) and may be due to greater variability and differences in disease severity. The significant improvement in lung function in patients treated with tiotropium vs. placebo in both smokers and ex-smokers suggests that tiotropium is an effective and well-tolerated therapy in chronic obstructive pulmonary disease (COPD), regardless of smoking status. r

show abstract

Section: Introductionmentioning

confidence: 99%

Tiotropium improves FEV1 in patients with COPD irrespective of smoking status

Moita¹,

Bárbara²,

Cardoso³

et al. 2008

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

show abstract

“…In another study conducted by the same author, smoking cessation rate was lower in females with COPD due to fear of weight gain, compared to male patients. [14] The study by Solak et al [15] reported a higher smoking cessation rate with the participation of smokers in smoking cessation programs, regular follow-up, and motivational support; however, they concluded that the presence of smoking-related diseases in any of the family members of an individual had no effect on the success of smoking cessation. Solak et al [16] also reported that professional support increased the success of smoking cessation attempts in cases with COPD; however, they concluded that the rate of smoking cessation was lower despite intensive support and regular follow-up, compared to healthy smokers (49% versus 29%).…”

Section: Discussionmentioning

confidence: 99%

Effects of smoking ban in Turkey on patients with chronic obstructive pulmonary disease: A retrospective analysis

Işıtmangil¹

2017

Turk Gogus Kalp Dama

View full text Add to dashboard Cite

ÖZAmaç: Bu çalışmada sigara yasağının kronik obstrüktif akciğer hastalığını önlemede etkili olup olmadığı araştırıldı. Bul gu lar: Sigara yasağı öncesi ve sonrasında hastaların sigara içme durumunda istatistiksel olarak anlamlı farklılık vardı (p= 0.002; p<0.01). Sigara içenlerin oranı yıldan yıla azalırken sigarayı bırakanların oranında artış vardı. Sigara yasağı öncesinde bir yılda geçirilen atak sayısı sigara yasağı sonrası bir yılda geçirilen atak sayısından yüksek olmakla beraber farklılık istatistiksel olarak anlamlılığa yakın idi (p=0.061; p>0.05).Sonuç: Çalışmamız sigara yasağının kronik obstrüktif akciğer hastalığı olan hastaların sayısını ve atak sayısını azalttığını gösterdi. Bu nedenle, tütün ürünlerinin kullanımının yasaklanmasının bu hastalığın önlenmesine yönelik stratejinin önemli bir parçası olduğunu önermekteyiz.Anahtar sözcükler: Kronik obstrüktif akciğer hastalığı; sigara yasağı; Türkiye. ABSTRACTBackground: This study aims to investigate whether smoking ban is effective in preventing chronic obstructive pulmonary disease.

show abstract

“…Dos ensayos clínicos han analizado la eficacia y la seguridad del uso de bupropión en el tratamiento de los fumadores con EPOC. Uno de ellos encontró que bupropión fue más eficaz que el placebo en obtener abstinencia continua a los 6 meses de seguimiento (16% frente al 9%; p < 0,05) (27). El otro mostró similares resultados, también a los 6 meses de seguimiento, con una diferencia del 18,9% (IC 95%: 3,6-34,2%); p = 0,02 (28).…”

Section: Discussionunclassified

Diagnóstico y tratamiento del hábito tabáquico en pacientes con EPOC. Estudio ADEPOCLE

Larriba¹,

Rodríguez²,

González‐Gallego³

et al. 2016

Nutr Hosp

View full text Add to dashboard Cite

11% (33.90-37.12) smokers diagnosed by cooximetry p < 0.05. 288 active smokers had low motivation (49.80%), high dependence (49.5%), negative attitude (52.60%), low mood (32.05%), with 2.72 (1.74-3.67) attempts to quit smoking, p < 0.0001. The conductive-behavioral therapy (CBT) combined with drug treatment was performed in 55.8% (52.2 to 54.9), p < 0.05; the most effective intervention was CBT combined with varenicline achieving an abstinence of 29.86%. A total of 51.05% (49.49 to 52.70) out of the patients with COPD stopped smoking, p < 0.001. Conclusions: The prevalence of smoking in COPD in our environment remains unacceptably high. Greater involvement is required to reduce its impact on the health of these patients.

show abstract

Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial

Cited by 374 publications

References 16 publications

Tiotropium improves FEV1 in patients with COPD irrespective of smoking status

Tiotropium improves FEV1 in patients with COPD irrespective of smoking status

Effects of smoking ban in Turkey on patients with chronic obstructive pulmonary disease: A retrospective analysis

Diagnóstico y tratamiento del hábito tabáquico en pacientes con EPOC. Estudio ADEPOCLE

Contact Info

Product

Resources

About